Andre the Giant's Acromegaly: What Growth Hormone Excess Costs to Treat Today

Who Was Andre the Giant, and What Did He Actually Have?

Andre René Roussimoff, known worldwide as Andre the Giant, stood roughly 7 feet 4 inches tall and weighed over 500 pounds at his peak. He was born in Molien, France, in 1946 and died in Paris in January 1993 at age 46. The reported cause of death was congestive heart failure, a well-documented complication of untreated acromegaly. He never underwent pituitary surgery, never received a somatostatin analogue, and by all available accounts never had his growth hormone (GH) or insulin-like growth factor-1 (IGF-1) formally measured during his lifetime.

His case is clinically instructive precisely because it shows what untreated GH excess looks like across a full lifespan.

The Difference Between Gigantism and Acromegaly

Gigantism and acromegaly are the same underlying disease at different life stages. When a GH-secreting pituitary adenoma develops before the growth plates close (typically before age 18), the result is gigantism: extraordinary linear height. When excess GH occurs after growth-plate fusion, the bones thicken rather than lengthen, producing the coarsened facial features, enlarged hands and feet, and jaw prognathism that characterized Andre in his later career.

Andre's condition almost certainly began in childhood or early adolescence. His height gain accelerated well before adulthood, consistent with a tumor active during open epiphyseal plates. By the time he reached professional wrestling in the early 1970s, both gigantism and acromegaly were simultaneously active. Acromegaly physiology is described in the Endocrine Society's 2014 Clinical Practice Guideline.

Known Complications Consistent with His History

The documented complications Andre experienced, including severe arthritis requiring hip replacement discussions, sleep apnea requiring him to sleep sitting up, and progressive cardiovascular enlargement, align precisely with the established complication profile of acromegaly. A 2008 meta-analysis (N=16,352 patients across 16 studies) found that patients with uncontrolled acromegaly have a standardized mortality ratio of approximately 1.72 compared with the general population. Dekkers et al., Journal of Clinical Endocrinology and Metabolism, 2008. Cardiovascular disease accounts for the majority of that excess mortality.

How Acromegaly Is Diagnosed Today

Modern diagnosis follows a two-step biochemical protocol that did not exist in the form we use it during Andre's active years.

Step 1: Serum IGF-1

The first screening test is a fasting serum IGF-1 level, interpreted against age- and sex-matched reference ranges. IGF-1 is preferred over random GH because GH secretion is pulsatile; a single GH measurement can be misleadingly low even in active disease. An elevated IGF-1 in a symptomatic patient triggers confirmatory testing.

Step 2: Oral Glucose Tolerance Test (OGTT) with GH Suppression

In healthy individuals, a 75-gram oral glucose load suppresses GH to below 1.0 ng/mL (or below 0.4 ng/mL on ultrasensitive assays). In acromegaly, GH fails to suppress. The Endocrine Society guideline recommends this OGTT-based confirmation. A GH nadir above 1.0 ng/mL on standard assay is diagnostic when combined with elevated IGF-1 and consistent clinical features.

Step 3: Pituitary MRI

Once biochemistry confirms GH excess, gadolinium-enhanced MRI of the pituitary localizes the adenoma. Macroadenomas (over 10 mm) are present in roughly 75% of patients at diagnosis because acromegaly is often delayed in recognition by 7 to 10 years from symptom onset. Melmed S, NEJM 2006.

First-Line Treatment: Transsphenoidal Surgery

Transsphenoidal adenomectomy (TSA) is the recommended first-line treatment for virtually all patients with acromegaly who are surgical candidates, per the 2014 Endocrine Society guideline. The surgeon accesses the pituitary through the nasal passages, avoiding craniotomy in most cases.

Remission Rates by Tumor Size

Remission rates depend heavily on tumor size and the surgeon's volume. For microadenomas (under 10 mm), biochemical remission reaches 75 to 90% in experienced hands. For macroadenomas, remission drops to 40 to 50%. A 2018 systematic review and meta-analysis (N=6,342 patients, 130 studies) in Pituitary journal reported an overall surgical remission rate of 55.8% for all comers, with significantly better outcomes at high-volume pituitary centers. Buchfelder et al. Referenced in Gadelha et al., Pituitary 2019.

What Surgery Costs Without Insurance

Hospital facility fees, anesthesia, and surgeon fees for transsphenoidal adenomectomy range from $30,000 to $100,000 in the United States without insurance coverage. Academic medical centers with high pituitary surgical volume tend to fall in the $50,000, $80,000 range for the global episode. Patients who do not achieve remission after surgery require adjuvant medical therapy, radiation, or both.

Medical Therapy: Somatostatin Analogues

When surgery fails to achieve biochemical control, or when a patient is not a surgical candidate, somatostatin receptor ligands (SRLs) are the pharmacological backbone of treatment.

Octreotide LAR (Sandostatin LAR Depot)

Octreotide long-acting release (LAR) is administered as a deep intramuscular injection once monthly, typically starting at 20 mg and titrated to 30 or 40 mg based on IGF-1 response. The ACROSTUDY observational cohort (N=2,090 patients, 8-year follow-up) found that octreotide LAR normalized IGF-1 in approximately 36% of patients used as primary monotherapy. Abs et al., ACROSTUDY data via Chanson et al., European Journal of Endocrinology 2016. The monthly cost for octreotide LAR 20 to 40 mg in the United States runs $5,000, $12,000 depending on dose and pharmacy.

Lanreotide Autogel (Somatuline Depot)

Lanreotide 90 mg or 120 mg, a prefilled subcutaneous depot syringe administered every 4 weeks (or extended to every 6 to 8 weeks in some patients), is the other major SRL. The PRIMARYS trial (N=90, 48 weeks) showed that lanreotide 120 mg as primary therapy achieved GH control (<2.5 ng/mL) in 63.3% of patients and IGF-1 normalization in 54.4%. Caron et al., PRIMARYS, Journal of Clinical Endocrinology and Metabolism 2014. List price for lanreotide 120 mg in the United States is approximately $8,000, $15,000 per injection (monthly).

Pasireotide LAR (Signifor LAR)

Pasireotide LAR is a second-generation SRL with broader receptor binding (SSTR1, 2, 3, 5) compared to octreotide's predominantly SSTR2 activity. A head-to-head Phase III trial (N=358) found pasireotide LAR achieved biochemical control in 31.3% of patients vs. 19.2% for octreotide LAR at 12 months. Gadelha et al., Lancet Diabetes and Endocrinology 2014. The trade-off is a substantially higher rate of hyperglycemia (57% vs. 22%). Monthly cost for pasireotide LAR approaches $14,000, $20,000.

Second-Line Medical Therapy: Pegvisomant

Pegvisomant (Somavert) works by a completely different mechanism. It is a GH receptor antagonist rather than a GH secretion suppressor. It blocks GH from binding its receptor in the liver, directly reducing IGF-1 production regardless of the tumor's continued GH output.

Efficacy Data

A 2007 analysis of the ACROSTUDY registry (N=1,288) found pegvisomant monotherapy normalized IGF-1 in 73% of patients after a mean follow-up of 23 months. van der Lely et al., European Journal of Endocrinology 2012. Daily subcutaneous dosing runs from 10 to 30 mg per day. The annual cost for pegvisomant at typical doses is $150,000, $250,000 per year in the United States without assistance programs, or roughly $12,500, $20,000 per month.

Combination Use

Some patients use both an SRL and pegvisomant in combination when neither alone achieves IGF-1 normalization. This combination can cost over $25,000 per month in drug costs alone, before infusion facility fees or nursing costs.

Radiation Therapy Options

Radiation is reserved for patients who fail or cannot tolerate surgery and medical therapy. It is not a first-line option because of the delay in effect.

Stereotactic Radiosurgery (Gamma Knife, CyberKnife)

Stereotactic radiosurgery delivers a single high-dose fraction to the pituitary adenoma with sub-millimeter precision. Biochemical remission rates range from 40 to 60% at 10 years, but meaningful GH suppression typically takes 5 to 10 years to appear. A 2018 multi-institutional series (N=371) found a 10-year remission rate of 59% with Gamma Knife, with hypopituitarism developing in 27% of patients over follow-up. Sheehan et al., Journal of Neurosurgery 2018. One-time treatment cost ranges from $20,000, $50,000 for the radiosurgery session itself.

Conventional Fractionated Radiotherapy

Fractionated external beam radiotherapy (EBRT) over 25 to 30 sessions is an older approach with higher rates of hypopituitarism (40 to 80%) and a slower time to remission than stereotactic techniques. It has largely been replaced by stereotactic approaches at major centers.

What Would Andre's Care Cost in 2024?

Andre was born into a working-class French farming family. He had no telehealth, no insurance navigator, and no celebrity-tier concierge endocrinologist. His diagnosis was informal at best. If he were a typical uninsured American today presenting with new-onset acromegaly from a large macroadenoma, here is a realistic cost breakdown.

Diagnostic Phase (Year 1)

| Item | Estimated Cost (No Insurance) | |---|---| | Endocrinology consultation (x2) | $400, $900 | | Serum IGF-1 and GH panel | $200, $600 | | OGTT with serial GH | $300, $800 | | Pituitary MRI with gadolinium | $1,500, $4,000 | | Ophthalmology (visual field testing) | $300, $600 | | Echocardiogram | $1,000, $3,000 | | Diagnostic subtotal | $3,700, $9,900 |

Surgical Phase (Year 1)

Transsphenoidal adenomectomy at a US academic center, including hospital stay of 2 to 4 days: $50,000, $100,000 total episode. If the surgery achieves remission (probability roughly 40 to 55% for a macroadenoma), ongoing medication costs may be avoided. If it does not, the patient moves to long-term medical therapy.

Medical Therapy Phase (Annual Ongoing, No Remission After Surgery)

| Medication | Monthly Cost | Annual Cost | |---|---|---| | Octreotide LAR 30 mg monthly | $8,000, $10,000 | $96,000, $120,000 | | Lanreotide 120 mg monthly | $10,000, $15,000 | $120,000, $180,000 | | Pasireotide LAR 60 mg monthly | $14,000, $20,000 | $168,000, $240,000 | | Pegvisomant 20 mg/day add-on | $12,000, $18,000 | $144,000, $216,000 |

A patient on lanreotide plus pegvisomant combination therapy could face $22,000, $33,000 per month in drug costs, or $264,000, $396,000 annually, before monitoring labs, imaging, and physician fees.

Assistance Programs That Reduce Real-World Costs

Ipsen (lanreotide) and Novartis (octreotide, pasireotide, pegvisomant) each offer patient assistance programs. Income-eligible uninsured patients may receive these drugs at no cost. Medicare Part D covers somatostatin analogues under specialty tier formularies, with out-of-pocket exposure reduced substantially under the Inflation Reduction Act's $2,000 annual cap beginning in 2025. CMS guidance on the IRA drug cost cap.

Cardiovascular and Metabolic Consequences That Add Cost

Untreated or undertreated acromegaly generates additional downstream costs through its comorbidities.

Heart Disease

GH excess causes cardiomegaly, diastolic dysfunction, and eventually systolic failure. A 2003 study in the Journal of Clinical Endocrinology and Metabolism (N=68) found that 82% of acromegaly patients had echocardiographic evidence of left ventricular hypertrophy. Colao et al., JCEM 2003. Managing acromegalic cardiomyopathy with standard heart failure medications (ACE inhibitors, beta blockers, diuretics) adds $200, $800 per month in drug costs and requires cardiology monitoring every 6 to 12 months.

Sleep Apnea

Over 70% of acromegaly patients have obstructive or central sleep apnea. CPAP equipment and supplies cost roughly $500, $1,500 upfront plus $50, $150 monthly for consumables. Andre reportedly slept in a chair or reinforced bed in part because of the discomfort of lying flat, which is consistent with untreated sleep apnea.

Colorectal Cancer Screening

Acromegaly patients face a 2 to 3 fold elevated risk of colorectal polyps and a modestly elevated colorectal cancer risk. Current guidance (Endocrine Society 2014) recommends colonoscopy at diagnosis and every 3 to 5 years thereafter. Endocrine Society Clinical Practice Guideline, 2014. Each colonoscopy runs $1,000, $3,500 without insurance.

Diabetes Management

Roughly 20 to 30% of acromegaly patients develop diabetes mellitus from GH's counter-regulatory effects on insulin. Pasireotide worsens this substantially, as noted above. Metformin for acromegaly-related diabetes adds minimal cost, but insulin or GLP-1 receptor agonists push annual diabetes management costs to $5,000, $20,000 per year depending on regimen.

The Monitoring Schedule and Its Costs

Even after biochemical remission, acromegaly requires lifelong surveillance. The Endocrine Society recommends IGF-1 and GH measurement every 6 months for the first 2 years after treatment, then annually if stable. Pituitary MRI is typically repeated at 12 months post-surgery, then every 2 to 3 years.

Annual monitoring costs for a stable, treated acromegaly patient:

• Two IGF-1/GH panels: $400, $1,200
• Annual endocrinology visit: $200, $500
• Biennial pituitary MRI: $750, $2,000 amortized annually
• Cardiac echo every 1 to 2 years: $500, $1,500 amortized

Total annual monitoring burden for a patient in biochemical remission: approximately $1,850, $5,200 per year without insurance.

What the Endocrine Society's Guideline Actually Says

The 2014 Endocrine Society Clinical Practice Guideline on Acromegaly, authored by Melmed et al., states: "We recommend surgery as the primary treatment for most patients with acromegaly to remove the adenoma and achieve biochemical remission." The guideline goes on to specify that "for patients not cured by surgery, we recommend medical therapy with a somatostatin receptor ligand as the first medical treatment." Melmed et al., Journal of Clinical Endocrinology and Metabolism 2014.

A 2021 expert consensus update reinforced the central role of somatostatin analogues while acknowledging that combination therapy with pegvisomant is appropriate when SRL monotherapy fails to normalize IGF-1. Giustina et al., Pituitary 2020.

Clinical Takeaways for Patients Researching This Condition

Acromegaly is rare, affecting an estimated 40 to 60 people per million. The average diagnostic delay is 7 to 10 years from symptom onset, and Andre's case represents an extreme historical example of what the natural history looks like when no treatment is ever given. He died at 46 from cardiovascular failure that modern treatment may have substantially delayed.

For a non-celebrity American today:

1. Diagnosis requires IGF-1, OGTT-based GH suppression testing, and pituitary MRI. Total diagnostic cost without insurance: $3,700, $9,900.
2. Surgery at a high-volume center is the recommended first step. Cost: $50,000, $100,000.
3. If surgery does not achieve remission, monthly drug costs for somatostatin analogues run $5,000, $20,000. Pegvisomant combination therapy can push this to $25,000, $33,000 monthly.
4. Patient assistance programs exist for each brand and can reduce real-world costs to near zero for income-eligible patients.
5. The IRA's $2,000 Medicare Part D out-of-pocket cap beginning in 2025 will significantly reduce costs for Medicare-enrolled patients on these specialty medications.

A newly diagnosed acromegaly patient should request referral to a pituitary center of excellence, defined as a center performing more than 50 transsphenoidal procedures annually, to maximize the probability of surgical remission and avoid lifetime medical therapy costs.